AIM:ORPH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£221.4m

Last Updated

2021/06/20 13:36 UTC

Data Sources

Company Financials +

Executive Summary

Open Orphan plc operates as a pharmaceutical service and contract research company. More Details


Snowflake Analysis

Mediocre balance sheet with limited growth.

Share Price & News

How has Open Orphan's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ORPH is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ORPH's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

-8.3%

ORPH

-1.6%

GB Life Sciences

-1.7%

GB Market


1 Year Return

173.3%

ORPH

24.8%

GB Life Sciences

16.0%

GB Market

Return vs Industry: ORPH exceeded the UK Life Sciences industry which returned 24.8% over the past year.

Return vs Market: ORPH exceeded the UK Market which returned 16% over the past year.


Shareholder returns

ORPHIndustryMarket
7 Day-8.3%-1.6%-1.7%
30 Day-7.8%-8.0%0.2%
90 Day8.2%-7.8%5.7%
1 Year173.3%173.3%25.5%24.8%21.6%16.0%
3 Yearn/a28.2%26.3%11.6%-1.3%
5 Yearn/a83.0%79.6%51.6%23.1%

Long-Term Price Volatility Vs. Market

How volatile is Open Orphan's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Open Orphan undervalued compared to its fair value and its price relative to the market?

9.89x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ORPH (£0.33) is trading above our estimate of fair value (£0)

Significantly Below Fair Value: ORPH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ORPH is unprofitable, so we can't compare its PE Ratio to the UK Life Sciences industry average.

PE vs Market: ORPH is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORPH is overvalued based on its PB Ratio (9.9x) compared to the GB Life Sciences industry average (4.6x).


Future Growth

How is Open Orphan forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

17.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ORPH's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if ORPH's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ORPH's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if ORPH's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ORPH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Open Orphan performed over the past 5 years?

-93.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ORPH is currently unprofitable.

Growing Profit Margin: ORPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ORPH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ORPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORPH is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-8.5%).


Return on Equity

High ROE: ORPH has a negative Return on Equity (-48.4%), as it is currently unprofitable.


Financial Health

How is Open Orphan's financial position?


Financial Position Analysis

Short Term Liabilities: ORPH's short term assets (£30.0M) exceed its short term liabilities (£24.0M).

Long Term Liabilities: ORPH's short term assets (£30.0M) exceed its long term liabilities (£2.2M).


Debt to Equity History and Analysis

Debt Level: ORPH's debt to equity ratio (1.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ORPH's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ORPH has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ORPH is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 5.1% per year.


Dividend

What is Open Orphan current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Trevor Phillips (59 yo)

1.42yrs

Tenure

Dr. Trevor Michael Phillips, B.Sc., Ph.D., M.B.A., serves as Chief Executive Officer at Open Orphan plc since January 2020 and served as Executive Director since January 17, 2020 until May 4, 2020. He is t...


Leadership Team

Experienced Management: ORPH's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: ORPH's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Open Orphan plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Open Orphan plc
  • Ticker: ORPH
  • Exchange: AIM
  • Founded: NaN
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£221.382m
  • Shares outstanding: 670.86m
  • Website: https://www.openorphan.com

Number of Employees


Location

  • Open Orphan plc
  • 10-12 Alie Street
  • 2nd Floor
  • London
  • Greater London
  • E1 8DE
  • United Kingdom

Listings


Biography

Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/20 13:36
End of Day Share Price2021/06/18 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.